About this Research Topic
CAR-T cell therapy represents an innovative form of immunotherapy, wherein T cells are genetically modified to recognize and target specific cancer cells, offering a personalized and targeted approach to cancer treatment. A chimeric antigen receptor (CAR) is a specially designed molecule comprised of an extracellular antigen-binding domain and an intracellular signaling domain, which together drive CAR-T cell activation upon antigen recognition. This breakthrough therapy has shown impressive clinical outcomes, particularly in hematological malignancies, with a significant number of patients achieving complete remission after failing conventional therapies. However, extending the success of CAR-T cell therapy to solid tumors presents unique challenges and opportunities.
This Research Topic aims to explore recent advancements and challenges in the pharmacology of CAR-T cell therapy, with a structured focus on its application in blood cancers and solid tumors separately.
CAR-T cell therapy has demonstrated remarkable efficacy in treating hematological malignancies, such as leukemia and lymphoma. Notable achievements include high rates of complete remission and significant improvements in overall survival for patients who have not responded to traditional treatments. On the other hand, the application of CAR-T cell therapy in solid tumors has been more challenging due to the complex and immunosuppressive tumor microenvironments.
By addressing the distinct challenges and advancements in CAR-T cell therapy for blood cancers and solid tumors, this Research Topic will provide comprehensive insights into the current state and future directions of this promising cancer treatment modality. Topics of interest include, but are not limited to:
• Mechanisms of CAR-T Cell Therapy
• Combination Therapies and Future Directions
• CAR-T Cell Manufacturing
• CAR Engineering
• CAR-T Cell Exhaustion
• CAR-T Cell Types (CD4+ vs CD8+ T cells, TSCM cells, Tregs, etc.)
• Liquid tumor vs. solid tumor targeting with CAR-T Cells
Researchers are encouraged to submit studies reporting on these aspects to contribute to the growing body of knowledge and optimize the clinical outcomes of CAR-T cell therapy for various cancer types.
This Research Topic aims to explore recent advancements and challenges in the pharmacology of CAR-T cell therapy, with a structured focus on its application in blood cancers and solid tumors separately.
CAR-T cell therapy has demonstrated remarkable efficacy in treating hematological malignancies, such as leukemia and lymphoma. Notable achievements include high rates of complete remission and significant improvements in overall survival for patients who have not responded to traditional treatments. On the other hand, the application of CAR-T cell therapy in solid tumors has been more challenging due to the complex and immunosuppressive tumor microenvironments.
By addressing the distinct challenges and advancements in CAR-T cell therapy for blood cancers and solid tumors, this Research Topic will provide comprehensive insights into the current state and future directions of this promising cancer treatment modality. Topics of interest include, but are not limited to:
• Mechanisms of CAR-T Cell Therapy
• Combination Therapies and Future Directions
• CAR-T Cell Manufacturing
• CAR Engineering
• CAR-T Cell Exhaustion
• CAR-T Cell Types (CD4+ vs CD8+ T cells, TSCM cells, Tregs, etc.)
• Liquid tumor vs. solid tumor targeting with CAR-T Cells
Researchers are encouraged to submit studies reporting on these aspects to contribute to the growing body of knowledge and optimize the clinical outcomes of CAR-T cell therapy for various cancer types.
Keywords: CAR-T cell, anti-cancer therapy, combination therapy, Chiemric antigen receptor, CAR-T cell exhaustion, cancer treatment, synthetic immunology, CAR engineering, T-cell subset, tumor microenvironment, biomarkers, pharmacokinetics, pharmacodynamics
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
